abstract: BACKGROUND: The evaluation of health-related quality of life (QOL) in @entity740 intends to quantify its consequences, according to the @entity1   s subjective perception. AIM: To evaluate the health-related QOL in four groups of @entity1 followed at our Nephrology Department: @entity740 ( @entity740 ) stages 1-4, kidney transplant (KT), haemodialysis (HD) and @entity298 ( @entity298 ) @entity1 . @entity1 AND METHODS: Thirty @entity1 with @entity740 stages 1-4 and 30 KT @entity1 were randomly selected. All @entity1 from our Haemodialysis and Peritoneal Dialysis Units with capacity to answer the inquiry (37 and 14, respectively) were also selected. The instruments applied were the SF-36 and KDQOL-SF 1.3. RESULTS: The four groups presented better results in the <Social Functioning > scale (77.68    18.46 in @entity298 ; 74.17    29.53 in KT; 66.81    31.39 in @entity740 1-4; 62.16    32.84 in HD; p = 0.192). The lowest results appeared in the <General Health> scale (39.92    19.12 in @entity740 ; 45.95    21.56 in HD; 47.13    23.15 in KT; 51.79    18.89 in @entity298 ; p = 0.321). Peritoneal dialysis @entity1 achieved the best results in the Physical Health Component, but this difference disappeared after adjustment to confounding factors. Age, gender and haemoglobin level were the variables related with QOL. However, @entity298 @entity1 obtained better scores comparing to HD @entity1 in the following KDQOL-SF scales: <Effects of @entity8 >, <Burden of @entity8 > and < @entity1 satisfaction> (p <0.05). CONCLUSIONS: Health-related QOL was better in @entity298 @entity1 comparing to haemodialysis @entity1 in specific scales of @entity740 . Age, gender and haemoglobin level interfered with health-related QOL.

title: Quality of life in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS', 'Patient']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['kidney disease']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['peritoneal dialysis', 'PD']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease']

answer: @entity740 :: (MESH:D051436,Disease) :: ['chronic kidney disease']


abstract: BACKGROUND: The @entity209 ( @entity209 ) refers to a cluster of cardiovascular risk factors that is associated with an increased risk of @entity73 and @entity303 . It is unclear however, if the presence of the @entity209 is associated with a particular clinical profile or a different prognosis in @entity1 with @entity73 or early @entity303 . OBJECTIVES: To compare 1) the clinical profile and 2) the prognosis of @entity1 attending a memory clinic according to the presence or absence of @entity209 . DESIGN: Longitudinal cohort. SETTING: Memory clinic. @entity1 : We included and followed 86 consecutive @entity1 (average age of 66.7 (SD 9.7)) from the Amsterdam @entity303 Cohort with an MMSE>22. MEASUREMENTS: Clinical profile (neuropsychological examination, brain MRI, cerebrospinal fluid (CSF) biomarkers, clinical diagnosis) on an initial standardized diagnostic assessment was compared according to @entity209 status. Progression to @entity303 was assessed in initially nondemented @entity1 (subjective complaints n=40, mild @entity73 n=24, follow-up available in 59). RESULTS: 35 (41%) @entity1 met the @entity209 criteria. Demographics were similar between @entity1 with or without the @entity209 . At baseline, diagnosis, cognitive performance, severity of @entity455 on MRI, and CSF amyloid and tau levels did not differ between the groups (all p>0.05). Among nondemented @entity1 , however, @entity209 was associated with worse performance on executive function, attention _ speed and visuoconstructive ability (z-scores, p<0.05). During a mean follow-up of 3.4years a similar proportion of @entity1 with (4; 17%) and without (6; 17%) the @entity209 progressed to @entity303 (p=0.45). CONCLUSION: Among nondemented @entity1 presenting at a memory clinic @entity209 was associated with slightly worse cognitive performance (worse on tasks assessing executive functions, visuo-constructive ability, attention _ speed), but conversion rate to @entity303 was not increased.

title: The XXXX in a memory clinic population: Relation with clinical profile and prognosis.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['degenerative or vascular abnormalities']

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['Dementia', 'dementia']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['cognitive complaints', 'cognitive impairment']

entities_list: @entity209 :: ('MESH:D008659', 'Disease') :: ['metabolic syndrome', 'MetS']

answer: @entity209 :: (MESH:D008659,Disease) :: ['metabolic syndrome']


abstract: OBJECTIVE: To determine whether low maternal serum concentrations of @entity1 chorionic gonadotropin ( @entity1465 ) were associated with poor pregnancy outcome. METHODS: Between 1999 and 2000, 20,880 @entity1 underwent triple test screening in our hospital. The levels of @entity1465 were detected by fluorescent immunoassay. Low @entity1465 levels (< or = 0.20 MoM in our center) were considered to be a marker for increased risk for trisomy 18 or adverse pregnancy outcome. Each @entity1 completed a questionnaire regarding fetal karyotype, complications of pregnancy and pregnancy outcome. RESULTS: Low maternal serum concentrations of @entity1465 were detected in 119 pregnancies (0.57%). Of these, 19 (16%) were found to be missed abortions. The distribution of the remaining 100 cases was as follows: 72% had an isolated low @entity1465 level, 24% had a low @entity1465 level and a combination of @entity1465 + alpha-fetoprotein < 0.80 MoM, and 4% had a low @entity1465 level and a combination of @entity1465 + unconjugated @entity11111 < 0.80 MoM. No trisomy 18 or other @entity2008 were detected in our @entity1 population. However, there were perinatal complications. CONCLUSION: Based on our screened population, a combination of multiple analytes seemed to be a better marker than an isolated finding of low maternal serum concentrations of @entity1465 with regards to abnormal fetal karyotype, specifically trisomy 18, although it did determine a high-risk group in terms of complications of pregnancy.

title: Low maternal serum concentrations of XXXX chorionic gonadotropin as part of the triple test screening: a follow-up study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'human', 'patient']

entities_list: @entity2008 :: ('MESH:D002869', 'Disease') :: ['chromosomal abnormalities']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: Weight and length measurements were recorded for 1583 babies during the 1st year of life. The population sample was fairly constant and composed of @entity1 from white, middle and upper income families seen in the private practice of 11 pediatricians in Dallas, Texas. This study was part of a larger research effort to determine how diets during the 1st 6 months affect subsequent development of @entity566 . The babies were subdivided into 3 groups according to family history for @entity566 and 3 groups according to diet ( @entity291 , breast or soy milk) during the 1st 6 months. After examination at birth, the babies were reexamined monthly up to 6 months of age and bimonthly thereafter up to age 1. Nearly 22,000 observations were made in all. Tables and charts were constructed showing mean weight and length measurements plotted from birth through 38 weeks against 24 possible combinations of sex, family @entity566 history, and diet. No significant difference was detectable between subgroups when differences in birth weight were taken into account. Compared with the Iowa norms for @entity1 growth which were established from measurements taken 1926-49, these babies grew taller in the 1st year of life; weight differences were minimal. Revised @entity1 growth charts, more consistent with today's growth patterns, are needed.

title: New growth charts: soy, XXXX , and breast milk comparison.

entities_list: @entity1 :: ('9606', 'Species') :: ['infant', 'children']

answer: @entity291 :: (9913,Species) :: ['cow']


abstract: OBJECTIVE: To determine if @entity302 surgery is effective in improving the quality of life (QOL) of @entity1 with intractable @entity410 using the Quality of Life in Childhood @entity302 Questionnaire (QOLCE). METHODS: The authors conducted a prospective study of the families of 35 @entity1 with intractable @entity302 who underwent @entity302 surgery. Parents completed the QOLCE preoperatively and again 6 to 18 months after surgery. At both assessment dates parents indicated the severity of their @entity1 's @entity410 during the past 6 months and the frequency of their @entity1 's @entity410 during the past 4 weeks on Likert-type scales. @entity1 were split into two groups according to surgery outcome: @entity410 free vs persistent @entity410 . Statistical analyses were conducted to determine if @entity1 rendered @entity410 free showed a greater improvement in QOL compared to those with persistent @entity410 postoperatively. RESULTS: Greater improvement in QOL was documented for @entity1 rendered @entity410 free vs @entity1 with persistent @entity410 . This was significant for the overall QOLCE QOL score and subscales assessing cognitive, social, emotional, behavioral, and physical domains of life. CONCLUSIONS: @entity302 surgery improves the quality of life of @entity1 rendered @entity410 free. Families can be counseled preoperatively of the potential benefits of surgery beyond @entity410 reduction.

title: The impact of XXXX surgery on quality of life in @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children', 'child']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy', 'Epilepsy']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: OBJECTIVE: @entity602 ( @entity602 ) has been applied to relieve @entity1118 for decades. Recent studies suggested that @entity602 also might alleviate @entity302 , but the most effective stimulation parameters are not known. The objective of this work was to investigate the role of @entity602 frequency in alleviating spike-and-wave (SW) discharges induced in @entity35 by @entity5093 ( @entity17202 ) infusion. MATERIALS AND METHODS: The SW discharges were induced in nine @entity35 . An epidural electrode was placed in the spinal canal at the cervical level. @entity602 was delivered at four frequencies (30, 80, 130 and 180   Hz) and compared with control intervals without stimulation. The effect was evaluated by analyzing electrocorticographic and intracortical (IC) signals. The means of normalized SW spike power (mSP) and frequency (mSF) were derived from the IC recordings and used to estimate the @entity410 severity. RESULTS: Compared with the control intervals, @entity602 conducted at 30   Hz significantly increased the mSP and mSF indicating an increase of the SW spiking activity; 80   Hz did not induce significant changes of the features. In contrast, 130- and 180-Hz @entity602 reduced both mSP and mSF significantly indicating a reduction of the SW spiking activity. CONCLUSIONS: The present results showed that 130-Hz and 180-Hz @entity602 reduced the SWs power and frequency which may indicate an anticonvulsive effect of these @entity602 frequencies, whereas 30-Hz @entity602 induced the opposite effects and, therefore, may be proconvulsive.

title: The Effect of Spinal Cord Stimulation on XXXX .

entities_list: @entity602 :: ('MESH:D013118', 'Disease') :: ['Spinal cord stimulation', 'SCS']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic seizures']

entities_list: @entity1118 :: ('MESH:D059350', 'Disease') :: ['chronic pain']

entities_list: @entity5093 :: ('MESH:D010433', 'Chemical') :: ['pentylenetetrazole']

answer: @entity302 :: (MESH:D004827,Disease) :: ['Epileptic Seizures']


abstract: Zymosan--a non-specific macrophage-stimulating agent--reduces @entity5 take in the liver. The mechanism for this effect is not clear, but it may be mediated via the Kupffer cells and @entity2918 . On the other hand, the Prostaglandin-synthesis inhibitor, @entity3352 , inhibits @entity5 growth. Pretreatment with @entity31156 (3 mg 100 g-1) for 3 days of two different strains of @entity35 , inoculated in the liver with a @entity157 or an @entity420 cell suspension respectively, reduced @entity5 take and also initial @entity5 growth. The effect on @entity5 take and initial growth was inhibited by concomitant administration of @entity3352 (0.2 mg 100 g-1). When zymosan was administered after @entity5 cell inoculation the growth rate of the @entity157 was retarded, but this effect was not abrogated by @entity3352 . Pretreatment with @entity3352 had no significant effect on @entity5 take or initial growth. When given after the @entity5 was established in the liver, @entity3352 reduced the growth rate of the @entity157 , but not of the @entity420 . These results suggest that there are different mechanisms for the effects of zymosan on @entity5 take and on growth of an established @entity5 . In immunoincompetent @entity19 the effect on the @entity157 was similar to the effect in the @entity35 . In vitro both @entity5 were insensitive to zymosan and @entity3352 . This study confirms that pretreatment with a non-specific macrophage stimulator (zymosan) diminishes @entity5 take and growth in the liver, that the effect of zymosan on @entity5 take in the liver is abrogated by @entity3352 and that the zymosan effect on @entity5 take in the liver is at least partly mediated by the Kupffer cells and @entity2918 .

title: Influence of zymosan (a non-specific macrophage stimulator) and of XXXX on liver tumours--an experimental study in @entity35 .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour', 'tumours']

entities_list: @entity2918 :: ('MESH:D011453', 'Chemical') :: ['prostaglandins']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatoma']

entities_list: @entity3352 :: ('MESH:D007213', 'Chemical') :: ['indomethacin']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

answer: @entity3352 :: (MESH:D007213,Chemical) :: ['indomethacin']


abstract: Nine pediatric @entity1 with moderate or severe @entity2348 (3 @entity295 or @entity2259 , 2 @entity3552 , @entity5389 , 1 @entity55 and 1 pyothorax) in hospital were treated with @entity2892 / @entity9234 . The drug was administered intravenously by 30 or 60 minutes drip infusion in 3 or 4 divided doses totalling 24 mg/24 mg-70.2 mg/70.2 mg per kg/day. Clinical effectiveness were excellent in 4 cases, good in 2 cases, poor in 2 cases and not evaluated in 1 case. The overall efficacy rate was 75%. A slight decrease of WBC was observed in 1 case. It was concluded that @entity2892 / @entity9234 was a useful antibiotic for the treatment of @entity281 in pediatric practices. Pharmacokinetics of intravenously administered @entity2892 / @entity9234 was studied in 2 other cases. The @entity2892 / @entity9234 was administered intravenously by 30 or 60 minutes drip infusion to 2 cases at a dose of 10 mg/10 mg/kg. The mean half-life (T1/2) of @entity2892 was 1.03 hours and @entity9234 , 0.69 hour. The mean urinary recovery rate of @entity2892 within 6.5-7 hours after administration was 62.5% and @entity9234 , 76.7%.

title: [Clinical evaluation of XXXX /cilastatin sodium in @entity1 ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['septicemia']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infections']

entities_list: @entity5389 :: ('MESH:D014069', 'Disease') :: ['2 tonsillitis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infections']

entities_list: @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremia']

answer: @entity2892 :: (MESH:D015378,Chemical) :: ['imipenem']


abstract: The developmental @entity137 of the anticonvulsant compound, @entity73207 , was investigated in @entity35 administered oral doses of 0, 15, 60, 120, 180, or 240 mg/kg on days 6 through 15 of gestation. An untreated control group and a vehicle control group pair-fed to the high dose group were included. Maternal and fetal parameters were evaluated on day 21 of gestation. Fetuses were examined for external, @entity600 and variations. @entity204 occurred at 180 and 240 mg/kg. Dose-dependent decreases in body weight, food consumption, and water consumption were observed at 60 mg/kg and above. Body @entity1017 during treatment was similar in the pair-fed and 240 mg/kg groups. Dose-related CNS signs ( @entity458 , @entity2055 , prostration, and/or @entity410 ) were observed at 60 mg/kg and above. Decreased numbers of live fetuses and increased postimplantation loss were observed in a dose-related manner at 120, 180, and 240 mg/kg while no changes occurred in pair-fed controls. Fetal body weights and placental weights were decreased in pair-fed controls and in the 120, 180, and 240 mg/kg groups. The percent fetuses per litter, and the percent litters with @entity600 , were significantly increased at 120, 180, and 240 mg/kg compared with vehicle and pair-fed controls. Dose-related @entity65 , specifically of the aortic arch (interrupted, stenotic, extra vessel), were apparent at 120 mg/kg and above. The incidence of skeletal variations was increased at 120 mg/kg and above.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Developmental @entity137 study in XXXX treated with the anticonvulsant, @entity73207 .

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['convulsions']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity458 :: ('MESH:D020018', 'Disease') :: ['hypoactivity']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['visceral, and skeletal malformations', 'external/visceral malformations']

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain']

entities_list: @entity73207 :: ('MESH:C054894', 'Chemical') :: ['ralitoline']

entities_list: @entity35 :: ('10116', 'Species') :: ['Sprague-Dawley rats']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['Maternal death']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['increases in cardiovascular malformations']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: BACKGROUND AND OBJECTIVES: Although resection of @entity242 with en bloc nephrectomy confers the potential benefit of improved @entity5 control, little has been published about the long-term post-operative renal function of these @entity1 . METHODS: Retrospective review of 54 @entity1 undergoing nephrectomy for @entity242 was performed. Clinicopathologic and treatment characteristics, pre- and post-operative @entity1011 ( @entity8818 ) values, and estimated glomerular filtration rates (eGFR) were recorded. The primary outcome measure was progression of @entity740 ( @entity740 ) stage. RESULTS: Median preoperative eGFR was 85   ml/min. Post-nephrectomy, median nadir eGFR was 44   ml/min, rebounding to 62   ml/min at median follow-up of 50 months. Of 49 @entity1 with preoperative eGFR >= 60   ml/min ( @entity740 stage 1,2), 51% preserved eGFR >= 60 postoperatively, whereas 49% progressed to @entity740 stage 3 (eGFR 30-59). Independent risk factors for progression of @entity740 stage were age and preoperative eGFR. Eleven @entity1 died of recurrent disease, whereas no @entity1 died of @entity454 ( @entity454 ) or required dialysis. CONCLUSIONS: Although progression of @entity740 stage occurs in nearly one-half of @entity1 followed for more than 4 years after nephrectomy for @entity242 , no @entity1 progressed to @entity454 or had a limitation in systemic therapy options, even with progression to @entity740 stage 3. J. Surg. Oncol. 2015 111:98-102.    2015 Wiley Periodicals, Inc.

title: Post-operative renal function following nephrectomy as part of en bloc resection of XXXX ( @entity242 ).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['locoregional tumor']

entities_list: @entity740 :: ('MESH:D051436', 'Disease') :: ['CKD', 'chronic kidney disease']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['ESRD', 'end stage renal disease']

answer: @entity242 :: (MESH:D012509,Disease) :: ['retroperitoneal sarcoma']


abstract: This paper reports our experience with a new over-the-scope @entity23396 in the setting of recurrent @entity548 . We treated five @entity1 with the over-the-scope Padlock @entity23396   . It is a @entity5648 ring, with six inner needles preassembled on an applicator cap, thumb press displaced by the Lock-It    delivery system. The trigger wire is located alongside the shaft of the endoscope, and does not require the working channel. Three @entity1 had recurrent @entity548 ( @entity548 rectal ulcer, post polypectomy delayed @entity548 and duodenal @entity75 ) and two @entity1 had a persistent @entity1576 . In all @entity1 a previous endoscopic attempt with standard techniques had been useless. All procedures were conducted under conscious sedation but for one @entity1 that required general anaesthesia due to multiple comorbidities. We used one Padlock @entity23396    for each @entity1 in a single session. Simple suction was enough in all of our @entity1 to obtain tissue adhesion to the instrument tip. A remarkably short application time was recorded for all cases (mean duration of the procedure: 8 min). We obtained technical and immediate clinical success for every @entity1 . No major immediate, early or late (within 24 h, 7 d or 4 wk) adverse events were observed, over follow-up durations lasting a mean of 109.4 d. One @entity1 , treated for duodenal bulb @entity548 from a @entity75 , developed signs of mild @entity788 24 h after the procedure. The new over-the-scope Padlock @entity23396    seems to be simple to use and effective in different clinical settings, particularly in "difficult" scenarios, like recurrent @entity548 and @entity1576 .

title: Novel endoscopic over-the-scope XXXX system.

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding lesions', 'bleeding', 'bleeding and oesophageal fistula']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ["Dieulafoy's lesion"]

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory-esophageal fistula', 'respiratory-oesophageal fistulas']

answer: @entity23396 :: (6249,Gene) :: ['clip']


abstract: @entity490 , but prolonged @entity221 may be the only symptom. Infectious abdominal @entity449 initially presenting with @entity693 are extremely rare; there are no reports of their successful treatment. Cases with @entity328 as the causative bacteria are even rarer with a higher mortality rate than those caused by other bacteria. We present the case of a 65-year-old @entity1 with lower limb @entity425 and @entity615 . Examination revealed @entity221 . Cerebrospinal fluid showed leukocytosis and low @entity413 levels. The @entity1 was diagnosed with @entity693 and @entity2259 caused by @entity328 and treated with antibiotics. @entity221 , inflammatory response, and neurologic findings showed improvement. However, abdominal computed tomography revealed an @entity439 not present on admission. Antibiotics were continued, and a @entity1215 soaked artificial vascular graft was implanted. Tissue cultures showed no bacteria, and histological findings indicated @entity32 with high leukocyte levels. There were no postoperative complications or @entity16 . Physical examination, blood tests, and computed tomography confirmed there was no relapse over the following 13 months. This is the first reported case of survival of a @entity1 with an @entity1028 initially presenting with @entity693 caused by @entity328 .

title: A Case Report on the Successful Treatment of @entity328 -Induced @entity1028 Initially Presenting with XXXX .

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity449 :: ('MESH:D001014', 'Disease') :: ['aortic aneurysms']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['Fever', 'fever and neck stiffness', 'fever']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurologic abnormalities']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['meningitis']

entities_list: @entity615 :: ('MESH:D001416', 'Disease') :: ['back pain']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm']

entities_list: @entity1028 :: ('MESH:D017544', 'Disease') :: ['infectious abdominal aortic aneurysm']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['Infectious abdominal aortic aneurysms often present with abdominal and lower back pain']

entities_list: @entity1215 :: ('MESH:D012293', 'Chemical') :: ['rifampicin']

entities_list: @entity328 :: ('1313', 'Species') :: ['Streptococcus pneumoniae']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

entities_list: @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremia']

answer: @entity693 :: (MESH:D008581,Disease) :: ['Meningitis']


abstract: INTRODUCTION: Two consensus conferences taking place in the United States and Spain were organized to optimize diagnosis and treatment of Candida spp. infections. Among other results, clinical scenarios in which early prescription of antifungal agents is indicated were identified. OBJECTIVE: To determine the criteria followed by physicians for prescribing antifungal agents in @entity3124 @entity1 in our country and to investigate adherence to the guidelines proposed by the consensus conferences. METHODS: A questionnaire was designed and directed to 4th- and 5th-year residents in intensive care medicine and to specialists in intensive care with training in @entity166 or other medical areas. Four case reports for which expert consensus indicates early antifungal treatment were included in the questionnaire; 1) recurrent @entity298 secondary to perforation of the digestive tract, with mixed flora including fungi; 2) persistent @entity221 in a @entity1 with @entity1049 treated with broad-spectrum antibiotics; 3) candiduria and @entity4658 in a febrile @entity1 ; and 4) @entity4963 . RESULTS: A total of 135 questionnaires from 45 different ICUs were returned (60% response rate). In the @entity4963 and @entity6378 examples, early treatment with antifungal agents was indicated in 100% and 85.9% of responses, respectively, whereas for @entity295 with @entity7553 and candiduria associated with @entity4658 and @entity221 , early treatment was prescribed in only 41.5% and 55.6% of responses, respectively. There were no significant differences in response with regard to degree of training of the physicians surveyed. @entity2380 prescription predominated, mainly at doses of 400 mg/day, in mixed @entity298 , @entity6831 , whereas @entity2379 lipid formulations were preferentially indicated in cases of @entity4963 . Antifungal treatment (early or late) was prescribed in all responses for @entity4963 , in 95.5% for mixed @entity298 (fungi and bacteria), in 79.5% for @entity7553 in @entity1 with persistent @entity295 , and in 77.9% for candiduria with @entity221 and @entity4658 . CONCLUSIONS: Adherence to recommendations from the consensus conferences was high among intensive medicine specialists, with no differences according to level of training in @entity166 .

title: [Treatment approach for fungal infections in @entity3124 XXXX admitted to intensive care units: results of a multicenter survey].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity2379 :: ('MESH:D000666', 'Chemical') :: ['amphotericin B']

entities_list: @entity2380 :: ('MESH:D015725', 'Chemical') :: ['Fluconazole']

entities_list: @entity3124 :: ('MESH:D016638', 'Disease') :: ['critically ill']

entities_list: @entity4963 :: ('MESH:D058387', 'Disease') :: ['candidemia']

entities_list: @entity6378 :: ('MESH:D010532', 'Disease') :: ['fungal peritonitis']

entities_list: @entity7553 :: ('MESH:D002177', 'Disease') :: ['multifocal candidiasis']

entities_list: @entity6831 :: ('MESH:D004673', 'Disease') :: ['disseminated candidiasis and candiduria']

entities_list: @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious diseases']

entities_list: @entity221 :: ('MESH:D005334', 'Disease') :: ['fever', 'febrile syndrome']

entities_list: @entity298 :: ('MESH:D010538', 'Disease') :: ['peritonitis']

entities_list: @entity1049 :: ('MESH:D003108', 'Disease') :: ['multiple mucosal fungal colonizations']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVES: Recent clinical trials have demonstrated that angiotensin-converting enzyme inhibitors (ACEIs) reduce @entity715 events by unknown mechanisms in @entity1 with @entity65 . DESIGN: We studied the in-vitro effects of @entity4687 , an ACEI, on the ability of @entity1 umbilical vein endothelial cells (HUVEC) to inhibit @entity1423 . METHODS: Platelet aggregation in the presence of HUVEC and endothelial surface expression and activities of ecto- @entity855 diphosphohydrolase (ecto-ADPase), @entity13796 , were determined. The capability of HUVEC to release @entity4770 and @entity842 (NO) was also investigated. RESULTS: Perindoprilat (an active metabolite of @entity4687 ) significantly enhanced the surface expression and activities of ecto-ADPase and @entity4770 release, resulting in enhancement of ability to inhibit @entity1423 by HUVEC. These effects of perindoprilat were also observed in HUVEC activated by @entity5 @entity39 factor ( @entity310 , which increased the expression of @entity2071 ( @entity2071 ), @entity2071 , and, despite up-regulation of @entity4770 release, attenuated endothelial anti-platelet properties by decreasing ecto-ADPase activity. Perindoprilat partially restored this capability, but failed to reduce enhanced expression of @entity2071 . By contrast, the role of NO as a platelet inhibitor appeared minimal in HUVEC. @entity1564 , an angiotensin II receptor ( @entity1129 (1)) blocker, did not affect endothelial anti-platelet property. CONCLUSIONS: Perindoprilat was found to augment endothelial capability to inhibit @entity1423 by increasing ecto-ADPase activity and @entity4770 release in HUVEC. This beneficial effect of perindoprilat appeared to be preserved in the activated cells exposed to @entity310 , although no evidence was found to support that it could reverse the @entity32 process induced by cytokines.

title: @entity4687 augments ecto- @entity855 diphosphohydrolase activity and enhances endothelial anti-platelet function in XXXX umbilical vein endothelial cells.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patients']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet aggregation']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity1564 :: ('MESH:C081643', 'Chemical') :: ['Candesartan']

entities_list: @entity4770 :: ('MESH:D011464', 'Chemical') :: ['prostacyclin']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

entities_list: @entity2071 :: ('3383', 'Gene') :: ['ICAM-1', 'intracellular adhesion molecule-1', 'CD54']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['atherosclerotic cardiovascular diseases']

entities_list: @entity4687 :: ('MESH:D020913', 'Chemical') :: ['perindopril']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: The effects of four dietary proteins on plasma @entity535 ( @entity3880 ) levels in portal vein and aorta and on hepatic @entity1423 were investigated in @entity35 fed 10% protein diets ad libitum. Proteins studied were beef, casein, rapeseed and @entity1460 . Measurements were made at 2000, 2300, 0200, 0500 and 0800 h. Portoaortic differences in essential @entity1522 (EAA) in plasma were calculated and compared to dietary EAA to verify the time-dependent changes in their intestinal absorption. Each protein generated different variations in portal and aortic @entity3880 levels. Rapeseed produced the lowest plasma concentrations of EAA, but its portoaortic differences were as large as those of the other proteins. With each protein, proportions of EAA in plasma (in contrast to concentrations) tended to remain constant in portal vein and aorta over the 12-h period. Significant correlations between portoaortic differences and dietary EAA were found in all groups, but at varying times, indicating that the kinetics of intestinal absorption were dependent on the protein fed. So were variations in liver polysome distribution. For rapeseed and @entity1460 , times of most active protein synthesis were 0200 and 0500 h; with beef and casein, variations between sampling times were not significant. No direct relationship was found between magnitude and composition of @entity3880 portoaortic differences and @entity1423 . Thus these two parameters were both affected by dietary proteins, but no synchrony was evidenced between them.

title: Effect of dietary proteins on time-dependent changes in plasma XXXX levels and on liver protein synthesis in @entity35 .

entities_list: @entity1522 :: ('CHEBI:33709', 'Chemical') :: ['amino acids']

entities_list: @entity1423 :: ('MESH:D001791', 'Disease') :: ['ribosome aggregation']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

answer: @entity535 :: (CHEBI:33704,Chemical) :: ['amino acid']


abstract: PURPOSE: Given the paucity of literature on outpatient @entity4037 repair (VHR), and that assessment of the safety of outpatient surgical procedures is becoming an active area of investigation, we have performed a multi-institutional retrospective analysis benchmarking rates of 30-day complications and readmissions and identifying predictive factors for these outcomes. METHODS: National surgical quality improvement project data files from 2011 to 2012 were reviewed to collect data on all @entity1 undergoing outpatient VHR during that period. The incidence of 30-day peri-operative complication and unplanned readmission was surveyed. We created a multivariate regression model to identify predictive factors for overall, surgical, and medical complications and unplanned readmissions with proper risk adjustment. RESULTS: 30-day complication and readmission rates in outpatient VHR were acceptably low. 3  % of the queried outpatients experienced an overall complication, 2.1  % a surgical complication, and 1.1  % a medical complication. 3.3  % of all @entity1 were readmitted within 30  days. Upon multivariate analysis, predictors of overall complications included age, BMI, history of @entity1030 ( @entity1030 ), and total operation time, predictors of surgical complications included age, BMI, total operation time, predictors of medical complications included total operation time, and predictors of unplanned readmissions included history of @entity1030 , @entity3459 , American Society of Anesthesiologists Class 3, 4, or 5, total operation time, and use of the laparoscopic technique. CONCLUSION: We have demonstrated that the risk of peri-operative morbidity in VHR as granularly defined in our study is low in the outpatient setting. Identification of predictive factors will be important to @entity1 risk stratification.

title: Assessing the safety of outpatient XXXX repair: a NSQIP analysis of 7666 @entity1 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity3459 :: ('MESH:D025861', 'Disease') :: ['bleeding disorder']

entities_list: @entity4037 :: ('MESH:D006555', 'Disease') :: ['ventral hernia']

entities_list: @entity1030 :: ('MESH:D029424', 'Disease') :: ['COPD', 'Chronic Obstructive Pulmonary Disease']

answer: @entity4037 :: (MESH:D006555,Disease) :: ['ventral hernia']


abstract: INTRODUCTION: Catheter ablation has become a well-established therapy for isthmus-dependent right @entity956 ( @entity956 ). Recently, mapping and ablation of @entity956 have been performed using sophisticated three-dimensional mapping systems, such as electroanatomic and noncontact mapping systems. The LocaLisa system enables nonfluoroscopic navigation of intracardiac electrode catheters based on impedance changes related to catheter movements in transthoracic current fields. The aim of this randomized prospective study was to compare the efficacy of the LocaLisa system with the conventional mapping/ablation approach for radiofrequency ablation of @entity956 . METHODS AND RESULTS: Fifty consecutive @entity1 with @entity956 (39 @entity1 and 11 @entity1 ; age 65 +/- 10 years) were studied. The @entity1 were randomly assigned to undergo radiofrequency ablation guided by a conventional fluoroscopy-based approach (24 @entity1 ) or by the LocaLisa system (26 @entity1 ). Ablation success rate and documentation of bidirectional isthmus block were 100% in both groups. Compared with fluoroscopy-guided approaches, LocaLisa-guided procedures demonstrated a reduction in total fluoroscopy time from 15.9 +/- 10.6 minutes to 7.5 +/- 6.5 minutes (P < 0.005). Total fluoroscopy dosage was reduced from 21.0 +/- 19.8 to 8.7 +/- 9.5 Gycm2 (P < 0.05). Fluoroscopy time required for ablation was significantly shortened in the LocaLisa group (2.6 +/- 2.6 min) compared with the conventional approach group (11 +/- 10 min, P < 0.0005). In 9 (35%) of 26 @entity1 , the ablation could be performed with a fluoroscopy time < or = 1 minute. There were no significant differences with regard to the number of radiofrequency applications, fluoroscopy time needed for diagnostic reasons, total procedure time, or other ablation data. CONCLUSION: Compared with the conventional approach, the LocaLisa system significantly reduces the fluoroscopy times needed for ablation of typical @entity956 .

title: LocaLisa catheter navigation reduces fluoroscopy time and dosage in ablation of XXXX : a prospective randomized study.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'men']

entities_list: @entity956 :: ('MESH:D001282', 'Disease') :: ['atrial flutter', 'AFL']

answer: @entity956 :: (MESH:D001282,Disease) :: ['atrial flutter']


abstract: @entity550 ( @entity550 ) has now become the preferred option for neurosurgical management of intractable central @entity9 such as post- @entity64 @entity158 and trigeminal @entity9 . However, the efficacy of @entity550 for other central @entity9 such as @entity158 resulting from spinal cord or @entity75 is unclear. We retrospectively reviewed 11 consecutive @entity1 with intractable central @entity9 who underwent @entity550 in our institution. Eight @entity1 had @entity158 caused by @entity548 (n = 5) or @entity1188 (n = 3) (thalamic group). Two @entity1 had postoperative @entity9 caused by @entity602 , and one @entity1 had @entity158 caused by a @entity75 associated with @entity15 (brainstem-spinal group). Visual analog scale and stimulation parameters were evaluated at 1 and 6 months postoperatively. @entity550 was effective for six of eight @entity1 in the thalamic group, and all three @entity1 in the brainstem-spinal group. These efficacies continued for 6 months after surgery without significant change in the stimulation parameters compared with the parameters at 1 month in both groups. The mean amplitude at 1 month and frequency at 6 months after surgery were significantly higher in the brainstem-spinal group than the thalamic group, although the @entity1 number was small. @entity550 is effective for other central @entity9 , but higher intensity stimulation parameters may be necessary to gain adequate @entity158 reduction.

title: Efficacy of motor cortex stimulation for intractable central XXXX : comparison of stimulation parameters between post- @entity64 @entity158 and other @entity158 .

entities_list: @entity550 :: ('MESH:D000303', 'Disease') :: ['Motor cortex stimulation', 'MCS']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['thalamic hemorrhage']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brainstem lesions', 'brainstem lesion']

entities_list: @entity602 :: ('MESH:D013118', 'Disease') :: ['spinal cord lesions']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarction']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['facial pain', 'pain', 'poststroke pain']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['multiple sclerosis']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']

answer: @entity9 :: (MESH:D009437,Disease) :: ['neuropathic pain']


abstract: BACKGROUND/PURPOSE: Thoracoscopic surgery has been increasingly utilized in treating pediatric @entity358 ( @entity358 ). Comparative studies evaluating 30-day outcomes between thoracoscopic and open resection of @entity358 are lacking. METHODS: There were 258 @entity1 identified in pediatric NSQIP with a @entity358 and pulmonary resection in 2012-2013. Comparisons of @entity1 characteristics and outcomes between surgical approaches were made using standard univariate statistics. In addition, a propensity score match was performed to evaluate outcomes in similar @entity1 cohorts. RESULTS: One-hundred twelve @entity1 (43.4%) received thoracoscopic resections and 146 @entity1 (56.6%) received open resections. @entity1 undergoing open resections were more likely to be less than 5months of age and have a comorbidity/preoperative condition (47.3% vs. 25.0%, p<0.001). The extent of resection was a lobectomy in 84.8% of thoracoscopic and 92.5% of open resection @entity1 . Median operative time was similar between both groups (thoracoscopic 172 vs. open 153.5minutes). On univariate analysis, thoracoscopic resection was associated with @entity260 (9.8% vs. 25.3%, p=0.001) and LOS (3 vs. 4days, p<0.001). However, after adjusting for similar @entity1 and operative characteristics, no significant differences were encountered between techniques. CONCLUSIONS: Thoracoscopic and open resection provide comparable 30-day outcomes and safety in the management of @entity358 .

title: Comparing 30-day outcomes between thoracoscopic and open approaches for resection of pediatric XXXX : Evidence from NSQIP.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['congenital lung malformations', 'CLM']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['decreased postoperative complications']

answer: @entity358 :: (MESH:D008171,Disease) :: ['congenital lung malformations']


abstract: BACKGROUND: The COMMIT/CCS-2 trial, published in 2005, demonstrated no net benefit of early b-blocker (BB) therapy in @entity1187 ( @entity1187 ). We sought to assess the short-term impact of this landmark trial by comparing the use of early BB therapy in @entity1 with a broad spectrum of @entity1187 before and after 2005. METHODS: Using data from the Global Registry of Acute Coronary Events and Canadian Registry of Acute Coronary Events, we compared the rates of BB use within the first 24 hours of presentation in the periods 1999 to 2005 and 2006 to 2008, after stratifying @entity1 by the type of @entity1187 ( @entity583 [ @entity583 ] and non-ST-segment elevation @entity1187 [NSTEACS]) and clinical presentation. RESULTS: Of the 14,231 @entity1 with @entity1187 , 77.7% received BB therapy within 24 hours of presentation (78.5% and 77.4% in the @entity583 and NSTEACS groups, respectively). The early use of BB declined in the @entity583 group (80.3% to 76.7%, P = .005) but increased in the NSTEACS group (75.4% to 78.9%, P < .001) after 2005. Long-term BB use, higher systolic blood pressure, and higher heart rate were independent predictors of early BB use. Conversely, @entity1 who were female, older, Killip class >1, and had @entity1167 at presentation were less likely to receive early BB. Multivariable analysis showed a trend toward lower use of BB among @entity1 with @entity583 (adjusted odds ratio 0.76, 95% CI 0.57-1.00, P = .055) and a trend toward more frequent BB use among @entity1 with NSTEACS (adjusted odds ratio 1.22, 95% CI 0.96-1.55, P = .11) after 2005. The temporal trends in the early use of BB differed between @entity1 with @entity583 and @entity1 with NSTEACS (P for interaction with period <.001). CONCLUSIONS: Most @entity1 with @entity583 or NSTEACS were treated with early BB therapy. In accordance with the COMMMIT/CCS-2 trial, @entity1 with lower systolic blood pressure and higher Killip class in the "real world" less frequently received early BB therapy. Since the publication of COMMIT/CCS-2, there has been no significant change in the use of BB in @entity1 with @entity583 or NSTEACS after controlling for their clinical characteristics.

title: Has the ClOpidogrel and Metoprolol in @entity583 Trial (COMMIT) of early b-blocker use in XXXX impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE).

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1187 :: ('MESH:D054058', 'Disease') :: ['ACS', 'acute coronary syndromes']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['STEMI', 'ST-segment elevation myocardial infarction']

entities_list: @entity1167 :: ('MESH:D006323', 'Disease') :: ['cardiac arrest']

answer: @entity1187 :: (MESH:D054058,Disease) :: ['acute coronary syndromes']


abstract: PURPOSE: @entity1 with reduced visual acuity (VA) and/or contrast sensitivity have difficulty recognizing faces and facial expressions. We have quantified these difficulties, using a synthetic face discrimination task employing both normal and artificially degraded vision. METHODS: VA and contrast thresholds were measured using an optimised staircase procedure [Freiburg acuity Test (FrACT)] in 25 young adults (aged 18-24 years) with corrected visual acuity of 0.0 logMAR or better and with four levels of vision degraded with @entity432 foils. For face discrimination, male face images were synthesised from 37 cardinal points (position of eyes, width of nose, head shape etc) derived from frontal face photographs and manipulated by altering the points as a fraction of the mean head radius. Face discrimination thresholds (% difference) were measured from a simultaneous four-alternative forced choice of 'odd one out' from three identical faces and one that differed. Psychometric functions were measured for four @entity1 with normal and degraded vision. Subsequently, the difference between faces was fixed at twice the discrimination thresholds and the size of the faces manipulated using the FrACT threshold procedure in 25 @entity1 . Data were converted to equivalent face discrimination distances for realistic face dimensions. RESULTS: With normal vision, face discrimination thresholds ranged from 2.7% to 5.6%; these increased systematically and were more variable with @entity227 . When manipulating face size, face discrimination distance was highly correlated with both acuity and contrast sensitivity (r(2) = 0.77 and 0.80 respectively, p < 0.01). The mean distance with normal vision was 15.3 m (14.5-16.2    S.E.M.). With vision degraded to 0.6 logMAR (6/24 Snellen, contrast threshold 15%) the mean face discrimination distance was reduced to 3.9 m (3.7-4.1,   S.E.M.). CONCLUSIONS: Poor face discrimination has a profound impact on real-life social communication. Here we report that artificial @entity227 also adversely impacts a synthetic face recognition task. As a rule of thumb, reduction in VA of 0.3 logMAR (halving the decimal VA) reduces the face recognition distance by a factor of 0.6 times. The FrACT-based face discrimination task provides an efficient new tool to quantify and monitor face discrimination ability.

title: The effects of XXXX on face discrimination.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'People']

entities_list: @entity227 :: ('MESH:D014786', 'Disease') :: ['visual degradation']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['Bangerter occlusion']

answer: @entity227 :: (MESH:D014786,Disease) :: ['visual degradation']


abstract: BACKGROUND: Thyroid antibodies (Thy-Abs) are frequently detected in various @entity792 in coexistence with other systemic autoantibodies. In association with an @entity75 , they are often taken as evidence of @entity14752 ( @entity14752 ). However, the presence of Thy-Abs in a cohort of @entity14204 ( @entity14204 ) @entity1 and their association with anti-neuronal autoimmunity has not been explored. @entity1 AND METHODS: We investigated thyroid and anti-neuronal antibodies in the sera of 24 @entity14204 @entity1 without identified @entity5 by cell-based assay and radioimmunoassay and evaluated their clinical features. RESULTS: There was a female predominance in Thy-Ab-positive @entity14204 @entity1 . Five of the eight Thy-Ab-positive @entity1 and six of the 16 Thy-Ab-negative patients had antibodies to voltage-gated @entity972 channel (VGKC), @entity1024 receptor (NMDAR) or undefined surface antigens on cultured hippocampal neurons. There were trends towards fewer VGKC antibodies (1/8 vs. 5/16, P = 0.159) and more NMDAR antibodies (2/8 vs. 1/16, P = 0.095) among the Thy-Ab-positive @entity14204 patients; antibodies to undefined surface antigens were only identified in Thy-Ab-positive @entity1 (2/8 vs. 0/16, P = 0.018). There were no distinguishing clinical features between Thy-Ab-positive @entity1 with and without neuronal antibodies. However, patients with anti-neuronal antibodies showed a better treatment response. CONCLUSION: Thy-Abs can be found in a high proportion of @entity1 with non-paraneoplastic @entity14204 , often in association with antibodies to specific or as yet undefined neuronal surface antigens. These results suggest that acute idiopathic @entity198 @entity1 with Thy-Abs should be closely monitored for ion-channel antibodies and it should not be assumed that they have @entity14752 .

title: Autoantibodies to neuronal surface antigens in thyroid antibody-positive and -negative XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity1024 :: ('CHEBI:31882', 'Chemical') :: ['N-methyl-D-aspartate']

entities_list: @entity198 :: ('MESH:D004660', 'Disease') :: ['encephalitis']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors']

entities_list: @entity14752 :: ('MESH:C535841', 'Disease') :: ['HE', "Hashimoto's encephalitis"]

entities_list: @entity972 :: ('MESH:D011188', 'Chemical') :: ['potassium']

entities_list: @entity792 :: ('MESH:D001327', 'Disease') :: ['autoimmune disorders']

entities_list: @entity14204 :: ('MESH:D020363', 'Disease') :: ['limbic encephalitis', 'LE']

answer: @entity14204 :: (MESH:D020363,Disease) :: ['limbic encephalitis']


abstract: @entity2227 is the principal excitatory neurotransmitter in the brain and, as such, it inevitably plays a role in the initiation and spread of @entity410 activity. It also plays a critical role in epileptogenesis. The process of "kindling" limbic @entity410 in rodents by repeated electrical stimulation is dependent on activation of @entity1024 ( @entity143 ) receptors. The function of these receptors is enhanced in the hippocampus of kindled @entity35 and in the cerebral cortex of @entity1 with @entity1625 . Microdialysis studies show an increase in the extracellular concentration of @entity2227 and @entity492 before or during @entity410 onset, suggesting that either enhanced @entity535 release or impaired uptake contributes to @entity410 initiation. @entity2227 antagonists selective for @entity143 or non- @entity143 receptors are potent anticonvulsants when given systemically in a wide variety of animal models of @entity302 . They are of limited efficacy against kindled @entity410 in @entity35 and (on the basis of preliminary evidence) in @entity1 with drug-refractory complex partial @entity410 . Cognitive side effects appear to be a significant problem with competitive, as well as noncompetitive, @entity143 antagonists. @entity2227 receptor antagonists provide significant protection against @entity75 following global or focal @entity2806 or acute @entity130 in rodent models. Anticonvulsant compounds of the @entity2812 type, which act on @entity1372 channels and reduce @entity63 -induced @entity2227 release, are cerebroprotective in rodent @entity63 models and are free from the cognitive side effects of @entity143 -receptor antagonists.

title: The role of @entity2227 in XXXX and other CNS disorders.

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate', 'Glutamate']

entities_list: @entity1625 :: ('MESH:D004828', 'Disease') :: ['focal epilepsy']

entities_list: @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemia']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['brain damage']

entities_list: @entity492 :: ('CHEBI:29995', 'Chemical') :: ['aspartate']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy']

entities_list: @entity2812 :: ('MESH:C047781', 'Chemical') :: ['lamotrigine']

entities_list: @entity130 :: ('MESH:D014947', 'Disease') :: ['traumatic injury']

answer: @entity302 :: (MESH:D004827,Disease) :: ['epilepsy']


abstract: @entity8719 -like lesions were induced in @entity35 by immunizing them with type II collagen. After seven months' immunization, the @entity35 were killed and processed for histologic study. We found @entity75 in the bony cochlea, vestibule, semicircular canal, and in the regions near the oval window and round window. The @entity75 in the otic capsules were similar to @entity1 @entity8719 and were characterized by the following types of microscopic appearances. 1) The classic type showed enlarged vascular spaces with congestion, macrophages, fibroblasts, and sometimes osteoclasts. 2) The fibrotic type showed vascular spaces filled with fibrous tissues. 3) The osteoporotic type had a porous appearance and was devoid of content. 4) The @entity3808 type showed bone spaces partially or entirely being replaced by new bone with blue mantles and a mosaic appearance. Some @entity75 showed a mixture of the above types. The findings suggest that this animal model may provide important information to help understand the process of @entity1 @entity8719 .

title: Type II collagen-induced XXXX -like lesions in @entity35 .

entities_list: @entity8719 :: ('MESH:D010040', 'Disease') :: ['otospongiosis', 'otosclerosis', 'Otospongiosis']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['spongiotic lesions', 'otospongiotic lesions']

entities_list: @entity3808 :: ('MESH:C538213', 'Disease') :: ['sclerotic']

answer: @entity8719 :: (MESH:D010040,Disease) :: ['otospongiosis']


abstract: OBJECTIVE: The @entity2694 results from damage to the nerves passing through the superior orbital fissure. In the present case, the @entity2694 developed after repair of @entity174 , although the symptoms were not observed before surgery and no obvious cause was found. To investigate the aetiology of this syndrome, we examined the superior orbital fissure anatomically. METHODS: We measured the width of superior orbital fissure on the horizontal plane including the optic canal using the computed tomography (CT) scans of other @entity1 and cadavers. RESULTS: The results indicated that the width was 3.73+/-1.64 mm in the CT scans of @entity1 and 3.21+/-1.09 mm in the cadavers. There was no significant difference between the width in the CT scans and cadavers. The width in the present @entity1 on the affected side was 1.6mm, that is relatively narrow. CONCLUSION: After operation, narrow superior orbital fissure may reduce the tolerance to compression of the nerves by @entity4 . We consider the narrow superior orbital fissure as a risk factor for @entity2694 . When the superior orbital fissure is congenitally narrow, the surgeons should try to avoid excessive pulling of the bone fragment and compression of the orbital tissue during repair of the @entity174 .

title: XXXX after repair of maxillary and naso-orbito-ethmoid fractures: a case study.

entities_list: @entity2694 :: ('MESH:D009916', 'Disease') :: ['superior orbital fissure syndrome']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4 :: ('MESH:D004487', 'Disease') :: ['oedema']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['facial bone fractures']

answer: @entity2694 :: (MESH:D009916,Disease) :: ['Superior orbital fissure syndrome']


abstract: BACKGROUND: Dietary surveys indicate that New Zealanders have a low intake of @entity15018 ( @entity13799 ) with little derived from industrial sources. This observational cross-sectional study in New Zealand @entity1 with surgical @entity453 assesses the plasma levels of @entity13799 and the association of @entity13799 levels with clinical markers of @entity455 . METHODS: 390 @entity1 with severe coronary artery had fasting blood tests taken. Plasma levels of four @entity13799 derived from hydrogenated vegetable oils and ruminant animal products were measured by gas chromatography. Relations between plasma @entity13799 levels and the recent occurrence of @entity583 , the presence of @entity66 , and serum levels of @entity1851 ( @entity1851 ) were assessed. RESULTS: The median @entity13799 level was 0.85% by weight of total @entity1718 (IQR 0.59-1.79%), with skewed distribution to the right. For the lowest (<0.74%), middle (0.74-1.07%), and highest (>1.07%) thirds of total @entity13799 , respectively, the proportion of @entity1 with @entity66 was 10%, 16%, and 27% (p   =   0.0004). Plasma @entity1851 also increased by tertile of @entity13799 (median 2.0, 2.9, 3.2   mg/l, p   =   0.007). The association with @entity66 and @entity1851 remained significant after adjustment for risk factors. Significant associations were present between plasma @entity13799 from both ruminant and hydrogenated vegetable oil sources and these markers of cardiovascular risk. CONCLUSIONS: There is an association between relatively low plasma levels of total @entity13799 , mostly derived from ruminant sources, and an increased risk of @entity66 and increased @entity1851 in @entity1 with severe @entity453 . These high-risk @entity1 may benefit from a targeted approach to minimize all sources of @entity13799 in the diet.

title: @entity15018 in New Zealand @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disease']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['polyvascular disease', 'polyvascular diseases']

entities_list: @entity15018 :: ('MESH:D044242', 'Chemical') :: ['trans-fatty acids']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity1718 :: ('MESH:D005227', 'Chemical') :: ['fatty acids']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary artery disease']


abstract: PURPOSE: To analyze the diagnostic accuracy of mammography, ultrasonography (US), and both methods combined in evaluation of palpable noncalcified @entity0 . MATERIAL AND METHODS: Mammograms and sonograms of 200 @entity1 with palpable noncalcified breast masses were retrospectively analyzed independently by four experienced radiologists in 3 sessions: Mammography or US interpretations in the first two and combined reading in the last session. @entity854 and mammographically obvious @entity5 were excluded. Receiver operating characteristic (ROC) analyses were performed for 115 (60 benign and 55 malignant) @entity5 and subgroups according to tissue density and @entity5 size. A single ROC curve for each diagnostic test was obtained by pooling the individual ratings. The area under the ROC curve was used as a measure of diagnostic performance. RESULTS: US revealed significantly higher diagnostic performance than mammography for @entity5 larger than 2 cm. Combined reading showed significantly higher performance than mammography except for @entity5 smaller than 2 cm. The performance of all three tests was reduced in dense parenchyma, and significantly so for mammographic and combined interpretation. CONCLUSION: The accuracy of US in @entity1 with palpable mammographically noncalcified and not obviously malignant @entity0 is lower than reported for mixed sample populations. The accuracy of US may be influenced by breast parenchyma density. Combined reading offers the highest diagnostic accuracy.

title: Diagnostic value of ultrasonography in XXXX with palpable mammographically noncalcified @entity0 .

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['Nonneoplastic abnormalities']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'tumors']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast tumors']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND/AIMS: To describe the clinical outcomes of @entity1 with circumscribed and diffuse @entity3193 treated by proton beam irradiation using a nonsurgical light-field technique. METHODS: A retrospective chart review was performed on a series of 19 @entity1 (19 eyes) with @entity3193 treated with proton beam therapy between July 1988 and August 2005. @entity3193 were treated with proton beam irradiation using a light-field technique and doses ranging from 15 to 30 cobalt Gray equivalents (CGE; CGE = proton Gy x relative biological effectiveness 1.1) in 4 fractions. @entity1 with at least 6 months' follow-up were included in the study. Tumor regression, visual acuity, absorption of subretinal fluid, and treatment-associated complications were evaluated by clinical examination and ultrasonography. RESULTS: Visual acuity improved or remained stable in 14 of 18 eyes (78%). Subretinal fluid was initially present in 16 of 19 eyes (84%), and completely resolved in all 16 eyes. Tumor height, as measured by B-scan ultrasonography, decreased in 18 of 19 eyes and remained stable in 1 of 19, as of the last examination. Complications of radiation developed in 9 of 19 eyes (47%) with the total applied dose ranging from 15 to 30 CGE for these 9 eyes. CONCLUSIONS: Proton beam irradiation using a light-field technique without surgical @entity5 localization is an effective treatment option in managing both circumscribed @entity3193 and @entity2695 associated with @entity3932 . A total proton dose as low as 15 CGE applied in 4 fractions appears to be sufficient to reduce @entity5 size, promote absorption of subretinal fluid, and improve or stabilize vision in most @entity1 .

title: Proton beam irradiation using a light-field technique for the treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity2695 :: ('MESH:D006391', 'Disease') :: ['diffuse hemangiomas']

entities_list: @entity3932 :: ('MESH:D013341', 'Disease') :: ['Sturge-Weber syndrome']

entities_list: @entity3193 :: ('MESH:D015862', 'Disease') :: ['Choroidal hemangiomas', 'choroidal hemangiomas']

answer: @entity3193 :: (MESH:D015862,Disease) :: ['choroidal hemangiomas']


abstract: BACKGROUND: The identification of @entity1 for targeted antineoplastic therapies requires accurate measurement of therapeutic targets and associated signaling complexes. @entity7514 signaling through heterodimerization is an important growth-promoting mechanism in several @entity5 types and may be a principal resistance mechanism by which @entity470 and @entity1722 expressing @entity5 elude targeted therapies. Current methods that can study these interactions are inadequate for @entity406 -fixed, @entity982 -embedded (FFPE) @entity5 samples. METHODOLOGY AND PRINCIPAL FINDINGS: Herein, we describe a panel of proximity-directed assays capable of measuring protein-interactions and phosphorylation in FFPE samples in the @entity7514 / @entity10412 / @entity584 pathway and examine the capability of these assays to inform on the functional state of the pathway. We used FFPE @entity0 cell line and @entity5 models for this study. In @entity0 cell lines we observe both ligand-dependent and independent activation of the pathway and strong correlations between measured activation of key analytes. When selected cell lines are treated with @entity1722 inhibitors, we not only observe the expected molecular effects based on mechanism of action knowledge, but also novel effects of @entity1722 inhibition on key targets in the HER receptor pathway. Significantly, in a xenograft model of delayed @entity5 fixation, @entity7514 phosphorylation is unstable, while alternate measures of pathway activation, such as formation of the HER3PI3K complex is preserved. Measurements in @entity0 samples showed correlations between @entity7514 phosphorylation and receptor interactions, obviating the need to use phosphorylation as a surrogate for @entity7514 activation. SIGNIFICANCE: This assay system is capable of quantitatively measuring therapeutically relevant responses and enables molecular profiling of receptor networks in both preclinical and @entity5 models.

title: Profiling the XXXX / @entity10412 pathway in @entity0 using proximity-directed assays identifies correlations between protein complexes and phosphoproteins.

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin']

entities_list: @entity982 :: ('MESH:D010232', 'Chemical') :: ['paraffin']

answer: @entity7514 :: (2065,Gene) :: ['HER3']


abstract: The adverse effects of opioids are well documented. Because opioid receptors have a wide-ranging anatomic distribution, the effects subsequent to opioid binding, both good and bad, occur centrally and in the periphery. Postoperative strategies to reduce opioid burden, therefore, are in the @entity1 's best interest. Multimodal @entity1337 is the key towards balancing the need for opioids while simultaneously reducing their burden. Alternative anesthesia and @entity1337 options such as regional anesthesia, nonsteroidal anti-inflammatory drugs, or @entity3840 enzyme inhibitors should be considered part of multimodal protocols. Familiarity of where these drugs are active in the body and how they can be employed is imperative for all surgical team members. Optimal implementation of multimodal approaches can reduce hospital stay and improve clinical outcomes, including @entity1 satisfaction. Finally, strategies that may help reduce rates of hospital readmission also contribute to overall improved outcome. New peripherally acting mu-opioid-receptor antagonists represent significant progress in the ability of perianesthesia nurses to play an even greater role in achieving these goals. In contrast to older opioid-receptor antagonists, these agents specifically target an important aspect of the multifactorial etiology of @entity86 ( @entity86 ), mu-opioid-receptor-mediated activity in the GI tract. In addition, they do not pass the blood-brain barrier or diminish opioid-mediated @entity1337 . Advanced clinical trials have already demonstrated the ability of one of these agents, @entity29141 , to reduce @entity86 and improve other postoperative outcomes while maintaining adequate @entity1337 . Combined with other options aimed at reducing opioid burden, alvimopan and similar drugs in development hold promise as part of multimodal protocols to optimize @entity158 management while minimizing postoperative morbidities.

title: Peripherally acting mu-opioid-receptor antagonists and the connection between @entity86 and XXXX management: The anesthesiologist's view and beyond.

entities_list: @entity1337 :: ('MESH:D000699', 'Disease') :: ['analgesia']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['POI', 'postoperative ileus']

entities_list: @entity29141 :: ('MESH:C419502', 'Chemical') :: ['alvimopan']

answer: @entity158 :: (MESH:D010146,Disease) :: ['pain']


abstract: Interactions of several muscarinic drugs with their receptors were studied in the ciliary body smooth muscles of the @entity95 . The ciliary body smooth muscles responded to @entity5402 , a muscarinic full agonist, with concentration-dependent contractions, and the pD2 value of @entity5402 was 5.16 +/- 0.05. @entity3897 , a competitive antagonist of muscarinic receptors, produced a parallel shift to the right in the concentration-response curves for @entity5402 . @entity2134 which is a well-known partial agonist on muscarinic receptors in most smooth muscles did not cause any contraction in this tissue. The drug, however, behaved as a competitive antagonist on the muscarinic receptors in the ciliary body smooth muscles. The pA2 values of @entity3897 and @entity2134 versus @entity5402 obtained from the Schild plot are 8.97 +/- 0.25 and 5.17 +/- 0.09, respectively. On the other hand, @entity6327 and @entity5592 acted as a partial agonist in this tissue. The intrinsic activity, and pD2 and pA2 values were 0.41 +/- 0.02, 4.93 +/- 0.05 and 5.32 +/- 0.05 for @entity6327 respectively, and were 0.26 +/- 0.02, 5.64 +/- 0.08 and 6.12 +/- 0.16 for @entity5592 , respectively. The pA2 values of these drugs were significantly larger than the corresponding pD2 values of the drugs. The values of the negative log molar dissociation constant of @entity5402 , @entity6327 and @entity5592 estimated by the method of partial irreversible blockade of spare receptors with 3 X 10(-6) M @entity5333 were 4.53 +/- 0.08, 5.20 +/- 0.09 and 6.02 +/- 0.06, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Muscarinic acetylcholine receptors in the XXXX ciliary body smooth muscle: spare receptors and threshold phenomenon.

entities_list: @entity2134 :: ('MESH:D010862', 'Chemical') :: ['Pilocarpine', 'pilocarpine']

entities_list: @entity5333 :: ('MESH:D010643', 'Chemical') :: ['phenoxybenzamine']

entities_list: @entity5592 :: ('MESH:D010095', 'Chemical') :: ['oxotremorine']

entities_list: @entity3897 :: ('MESH:D001285', 'Chemical') :: ['Atropine', 'atropine']

entities_list: @entity5402 :: ('MESH:D002217', 'Chemical') :: ['carbachol']

entities_list: @entity6327 :: ('MESH:D001115', 'Chemical') :: ['arecoline']

answer: @entity95 :: (9986,Species) :: ['rabbit']


abstract: A national registry for @entity1577 was established in France in 1993. A questionnaire is sent once a year to different health care units. The first questionnaire was analyzed in 1992: 1,893 @entity1 (53% males) were identified. 28% were over 15 years of age, 13% more than 20, and 1% over 35. Usually, diagnosis had been suggested by respiratory signs, followed by digestive tract signs and @entity851 and meconial ileus. 13% were diagnosed in screening programmes. Diagnosis was made before 1 year in 66% of the subjects (mean = 7 months). All the data collected and the functional and bacteriologic data were compared with those observed in the United States and Canada. It should also be noted that 38 @entity1 were grafted during this study year and that it is too early to analyze the general outcome for all subjects. The creation of this registry is an important step towards a better understanding of the epidemiology of @entity1577 in the French population.

title: [ XXXX : comparative analysis of epidemiological data of French and North American registries].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['growth impairment']

entities_list: @entity1577 :: ('MESH:D003550', 'Disease') :: ['cystic fibrosis']

answer: @entity1577 :: (MESH:D003550,Disease) :: ['Mucoviscidosis']


abstract: UNASSIGNED: @entity3 have been shown to establish microenvironments in distant tissues that are permissive to disseminated @entity5 cells. @entity1583 cells contribute to this microenvironment, yet the precise initiating events responsible for establishing the pre-metastatic niche remain unclear. Here, we tracked the developmental fate of hematopoietic stem and progenitor cells (HSPC) in @entity5 -bearing @entity19 . We show that a distant @entity5 drives the expansion of HSPCs within the bone marrow and their mobilization to the bloodstream. Treatment of purified HSPCs cultured ex vivo with @entity5 -conditioned media induced their proliferation as well as their differentiation into immunosuppressive myeloid cells. We furthered tracked purified HSPCs in vivo and found they differentiated into myeloid-derived suppressor cells in early metastatic sites of @entity5 -bearing @entity19 . The number of @entity3804 (+) @entity17775 (+) cells in metastatic sites was significantly increased by HSPC mobilization and decreased if @entity5 -mediated mobilization was inhibited. Moreover, pharmacologic mobilization of HSPCs increased metastasis, whereas depletion of Gr1(+) cells abrogated the metastasis-promoting effects of HSPC mobilization. Finally, we detected elevated levels of HSPCs in the circulation of newly diagnosed @entity5 @entity1 , which correlated with increased risk for metastatic progression. Taken together, our results highlight bone marrow activation as one of the earliest steps of the metastatic process and identify circulating HSPCs as potential clinical indicators of metastatic niche formation. @entity5 Res; 76(6); 1-13.   2015 AACR.

title: Activation of XXXX Stem/Progenitor Cells Promotes Immunosuppression Within the Pre-metastatic Niche.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'primary tumor', 'Cancer']

entities_list: @entity1583 :: ('MESH:D019337', 'Disease') :: ['Hematopoietic']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['Metastatic tumors']

answer: @entity1583 :: (MESH:D019337,Disease) :: ['Hematopoietic']


abstract: BACKGROUND: Five-Year survival after pelvic exenteration for gynecologic @entity5 has been reported as high as 60%. The objective of this study was to determine @entity1349 ( @entity1349 ) after pelvic exenteration and evaluate factors impacting outcome. METHODS: A retrospective review of all @entity1 who underwent pelvic exenteration at our institution between February 1993 and December 2010 was performed. @entity1349 was defined as time from exenteration to date of @entity204 or last contact. Survival analysis was performed using the Kaplan Meyer method. Multivariate analysis was performed to determine the impact of clinical and pathologic factors on survival outcomes. RESULTS: One hundred sixty @entity1 with gynecologic @entity5 underwent pelvic exenteration. Five-year @entity1349 ( @entity1349 ) was 33% (95%CI 0.25-0.40). Factors which negatively impacted @entity1349 included shorter treatment-free interval (p=.050), vulvar primary (p=.032), positive margins (p<.001), lymphovascular space invasion (LVSI, p<.001), positive lymph nodes (p<.001) and perineural invasion (p=0.030). In multivariate analysis, positive margins (p=.040), positive nodes (p<.001) and lymphovascular space invasion (LVSI, p=.003) retained a significant impact on @entity1349 . Five-year @entity1349 was 40% (95% CI 0.32-0.48). Factors which negatively impacted @entity1349 included vulvar primary (p=.04), positive margins (p<.001), LVSI (p<.001), positive lymph nodes (p<.001) and perineural invasion (p=.008). In multivariate analysis, positive nodes (p=.001) and LVSI (p=.001) retained a significant impact on @entity1349 . CONCLUSION: Five-year @entity1349 after pelvic exenteration was 40%. Survival outcomes have not significantly improved despite improvements in technique and @entity1 selection. Multiple non-modifiable factors at the time of exenteration are associated with poor survival.

title: Overall survival after pelvic exenteration for gynecologic XXXX .

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['malignancy', 'malignancies']

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'recurrence free survival', 'RFS', 'overall survival']

answer: @entity5 :: (MESH:D009369,Disease) :: ['malignancy']


abstract: INTRODUCTION: @entity72044 ( @entity72044 ) are among major causes of mortality in @entity1 with @entity1583 . @entity325 develop either during the empirical antibiotic therapy or one week after cessation of therapy for a FNE. The aim of the study was to investigate the risk factors associated with secondary infections in febrile neutropenic @entity1 . METHODS: We retrospectively analyzed 750 @entity72044 in 473 @entity1 between January 2000 and December 2006. RESULTS: @entity325 were diagnosed in 152 (20%) of 750 @entity72044 . The median time to develop secondary infection was 10 days (range 2-34 days). The duration of @entity1398 over 10 days significantly increased the risk of secondary infections (p<0.001). The proportion of @entity1 with microbiologically documented infections was found to be higher in primary infections (271/750, 36%) compared to secondary infections (43/152, 28%) (p=0.038). Age, sex, underlying disease, antibacterial, antifungal or antiviral prophylaxis, blood transfusion or bone marrow transplantation, central venous catheter or severity of @entity1398 did not differ significantly between primary and secondary infections (p>0.05) While fever of unknown origin (FUO) (p=0.005) and catheter-related @entity2259 (p<0.001) were less frequently observed in secondary infections, the frequency of microbiologically (p=0.003) and clinically (p<0.001) documented infections, @entity364 (p<0.001), infections related with gram positive bacteria (p=0.04) and fungi (p<0.001) and 30-day mortality rate (p<0.001) were significantly higher in secondary infections (p<0.001). DISCUSSION AND CONCLUSION: @entity325 should be regarded as life-threatening complications of @entity1398 . @entity325 represent a more severe and mortal complication and cannot be regarded just as another febrile neutropenic episode.

title: Secondary Infections in XXXX in @entity1583 : More Than Another Febrile Neutropenic Episode.

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia', 'febrile neutropenia']

entities_list: @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal pneumonias']

entities_list: @entity325 :: ('MESH:D060085', 'Disease') :: ['Secondary infections']

entities_list: @entity1583 :: ('MESH:D019337', 'Disease') :: ['hematological malignancies']

entities_list: @entity72044 :: ('MESH:D064147', 'Disease') :: ['FNEs', 'Febrile neutropenic episodes']

entities_list: @entity2259 :: ('MESH:D016470', 'Disease') :: ['bacteremia']

answer: @entity1398 :: (MESH:D009503,Disease) :: ['Febrile Neutropenia']


abstract: BACKGROUND: Recurrent @entity8 (rFSGS) in renal transplant recipients (RTR) is difficult to predict and treat. Early rFSGS is likely from circulating factors and preformed antibodies. METHODS: We present the case of a 23-year-old white @entity1 who presented with rFSGS and @entity810 , requiring dialysis 9-months after a 1-haplotype matched living-related transplant. We retrospectively analyzed serum samples from various clinical stages for rFSGS biomarkers: serum glomerular albumin permeability (Palb), soluble urokinase-type plasminogen activator receptor (suPAR) serum level with suPAR-b3 integrin signaling on @entity1 podocytes, and angiotensin II type I receptor-antibody ( @entity7743 -Ab) titer. RESULTS: All biomarkers were abnormal at 1-year pre-transplant prior to initiation of dialysis and at the time of transplant. After initiation of hemodialysis, b3 integrin activity on @entity1 podocytes, in response to patient serum, as well as @entity7743 -Ab were further elevated. At the time of biopsy-proven recurrence, all biomarkers were abnormally high. One week after therapy with aborted plasmapheresis (secondary to intolerance), and high dose @entity230 , the Palb and suPAR-b3 integrin activity remained significantly positive. After 12-weeks of treatment with high-dose @entity230 , rituximab, and @entity3649 , the @entity1 remained hemodialysis-dependent. Three-months after his initial presentation, we commenced @entity4545 (ACTH, Acthar(  ) Gel), 80 units subcutaneously twice weekly. Four-weeks later, he was able to discontinue dialysis. After 8-months of maintenance ACTH therapy, his serum @entity1011 stabilized at 1.79   mg/dL with <1   g of @entity644 . CONCLUSION: ACTH therapy was associated with improvement in renal function within 4   weeks. The use of rFSGS biomarkers may aid in predicting development of rFSGS.

title: A case report of @entity4545 to treat recurrent XXXX post-transplantation and biomarker monitoring.

entities_list: @entity1 :: ('9606', 'Species') :: ['human', 'patient', 'man']

entities_list: @entity4545 :: ('5443', 'Gene') :: ['adrenocorticotropic hormone']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['focal segmental glomerular sclerosis']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity3649 :: ('MESH:D005690', 'Chemical') :: ['galactose']

entities_list: @entity810 :: ('MESH:D058186', 'Disease') :: ['acute renal failure']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

answer: @entity8 :: (MESH:D007674,Disease) :: ['focal segmental glomerular sclerosis']


abstract: PURPOSE: To analyze the adverse events (AEs) significantly associated with @entity4677 ( @entity29279 ) therapy through a meta-analysis of all available double-blind, randomized placebo-controlled trials (RCTs), performed in any age, gender, ethnic background and disease. General tolerability and study withdrawals due to AEs associated with @entity29279 treatment were also investigated. In addition, a dose-effect responses relationship for all variables was assessed. METHODS: RCTs were identified searching Medline (PubMed), Embase and Cochrane CENTRAL for the words " @entity4677 " and "randomized controlled trial", with different search strategies, setting the limits " @entity1 " and "English". Very common and common AEs according to the summary of product characteristics were investigated. RevMan version 5.2 was used for the statistical analyses. Risk difference with 95% confidence intervals was used to investigate the association of any AEs and withdrawal with @entity29279 . RESULTS: Twenty-six studies with 2832 @entity1 were included in the RCTs analysis. @entity11266 , @entity2147 , dizziness, nervousness/ @entity146 and @entity1395 / @entity1295 were statistically significant associated with @entity29279 . In addition, @entity29279 was significantly associated with an increased risk of AEs-related withdrawals. No dose-response relationship was found for any of the assessed variables. CONCLUSIONS: This first large meta-analysis suggests that @entity1 were more likely to discontinue @entity29279 than placebo. The AE profile confirmed that @entity29279 is associated with few unfavorable sedative, vestibulocerebellar and behavioral effects, such as nervousness and @entity146 . However, there does not seem to be a clear dose-response relationship.

title: The adverse event profile of XXXX : A meta-analysis on @entity1 and adults.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'humans', 'patients']

entities_list: @entity4677 :: ('MESH:C026098', 'Chemical') :: ['levetiracetam', 'Levetiracetam']

entities_list: @entity11266 :: ('MESH:D009304', 'Disease') :: ['Nasopharyngitis']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['irritability']

entities_list: @entity2147 :: ('MESH:D006970', 'Disease') :: ['somnolence']

answer: @entity4677 :: (MESH:C026098,Chemical) :: ['levetiracetam']


abstract: OBJECTIVE: To test if @entity4905 / @entity64 electronic decision support in primary care improves management. METHODS: Multicenter, single-blind, parallel-group, cluster randomized, controlled trial comparing @entity4905 / @entity64 electronic decision support guided management with usual care. Main outcomes were guideline adherence and 90-day @entity64 risk. Secondary outcomes were cerebrovascular/vascular/ @entity204 /adverse events, cost, and user feedback. Main analysis was logistic regression with a normal random effect for clusters using a generalized linear mixed model. RESULTS: Twenty-nine clinics were randomized to intervention, 27 to control, recruiting 172 and 119 eligible @entity1 . More intervention @entity1 received guideline-adherent care (131/172; 76.2%) than control @entity1 (49/119; 41.2%) (adjusted odds ratio [OR] 4.57; 95% confidence interval [CI] 2.39-8.71; p < 0.001). Ninety-day @entity64 occurred in 2/172 (1.2%) intervention and 5/119 (4.2%) control @entity1 (OR 0.27; 95% CI 0.05-1.41; p = 0.098). Ninety-day @entity4905 or @entity64 occurrence was lower in the intervention group, 4/172 (2.3%) compared to 10/119 (8.5%) control (adjusted OR 0.26; 95% CI 0.70-0.97; p = 0.045). Fewer vascular events/ @entity204 occurred in intervention, 6/172 (3.5%), than in control @entity1 , 14/119 (11.9%) (adjusted OR 0.27; 95% CI 0.09-0.78; p = 0.016). Treatment cost ratio of 0.65 (95% CI 0.47-0.91; p = 0.013) favored the intervention without increased adverse events. Clinician feedback was positive. CONCLUSION: Primary care use of the @entity4905 / @entity64 electronic decision support tool improves guideline adherence, safely reduces treatment cost, achieves positive user feedback, and may reduce cerebrovascular and vascular event risk following @entity4905 / @entity64 . CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that a primary care electronic decision support tool improves guideline adherence and might reduce 90-day @entity64 risk.

title: Cluster randomized controlled trial of XXXX electronic decision support in primary care.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['death', 'deaths']

answer: @entity4905 :: (MESH:D002546,Disease) :: ['TIA']


abstract: Either four or eight weekly rituximab infusions in relapsed or refractory low-grade or follicular B cell @entity1893 ( @entity1893 ) are well tolerated and efficacious. This phase II trial investigated the safety and efficacy of six weekly rituximab doses in chemotherapeutically pre-treated relapsed or refractory low-grade @entity1893 @entity1 . Sixty-eight @entity1 (median age 64 years) received six i.v. rituximab infusions 375 mg/m2 weekly. All @entity1 had received one or more prior therapies (median 2; range 1-18). Forty-two @entity1 had @entity74 and were evaluated for @entity137 and efficacy; 12 of these required re-treatment with six weekly rituximab infusions. Twenty-six @entity1 received rituximab as remission consolidation therapy and were assessed for @entity137 only. No @entity1 discontinued because of adverse events. Most adverse events were National Cancer Institute grade 1 (2-9%) or 2 (3-5%) and usually occurred during the first infusion. No @entity1503 were observed. Overall response rate was 59% (median time to response 2 weeks) and 10 of 12 re-treated @entity1 responded. Median time to progression for all @entity1 was 14 months and for responders 21 months. More than half the 42 @entity1 evaluated for efficacy and more than 70% of the 25 responding @entity1 still survived longer than 3 years after treatment. The safety profile and efficacy achieved in this study compare favorably with those seen with four or eight weekly doses in pre-treated low-grade @entity1893 .

title: Semi-extended, six weekly rituximab infusions in pre-treated advanced low-grade B cell XXXX : a phase II study.

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematological abnormalities']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['progressive disease']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphoma", 'NHL']

answer: @entity1893 :: (MESH:D008228,Disease) :: ['non-Hodgkin's lymphoma']


abstract: BACKGROUND: Survival was prolonged in selected @entity1 with sustained @entity943 who received @entity737 ( @entity737 ) in the @entity2132 ( @entity2132 ) study. The Midlands trial of empirical @entity2643 versus electrophysiologically guided intervention and cardioverter implant in @entity943 (MAVERIC) registry is a population based trial. OBJECTIVE: To determine the number of @entity1 who satisfy the @entity2132 criteria because of the high cost of @entity737 . DESIGN: Observational study, based on a continuing trial. SETTING: All coronary care units in the Midlands region in the United Kingdom (population 9.1 million). @entity1 : @entity1 presenting to a coronary care unit with sustained @entity943 not related to an acute @entity583 are entered onto the registry. Those who consent to the MAVERIC study are randomised to receive either empirical @entity2643 or electrophysiologically guided treatment. Demographic data, details of clinical presentation, and echocardiographic findings are collected. These data have been used to calculate the number of @entity1 who satisfy the @entity2132 criteria and would benefit from @entity1479 implantation. The financial implications have been calculated for the region and nationally. RESULTS: 132 @entity1 were entered onto the registry during the first five months of the MAVERIC study; 69 @entity1 fulfilled the @entity2132 criteria. Extrapolation of these data over a 12 month period suggests implantation of at least 166 new @entity737 (compared with 23 implants in 1996). This would increase the UK @entity1479 implant rate from five to at least 18 per million of the population, costing the National Health Service 24.1 Pounds million per annum. CONCLUSION: Application of the @entity2132 criteria in the UK will cause a great increase in the @entity1479 implant rate, with serious financial implications.

title: Potential impact of antiarrhythmic drugs versus implantable defibrillators on the management of @entity943 : the Midlands trial of empirical XXXX versus electrophysiologically guided intervention and cardioverter implant registry data.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity2643 :: ('MESH:D000638', 'Chemical') :: ['amiodarone']

entities_list: @entity737 :: ('MESH:D057873', 'Disease') :: ['ICDs', 'implantable cardioverter defibrillators']

entities_list: @entity2132 :: ('MESH:D006086', 'Disease') :: ['antiarrhythmics versus implantable defibrillators', 'AVID']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmias']

answer: @entity2643 :: (MESH:D000638,Chemical) :: ['amiodarone']


abstract: BACKGROUND: @entity1662 are costly and challenging conditions to treat. Although recent studies that have tested pharmacological and electrical stimulation for these conditions are promising, the optimal intervention, mechanisms of action and side effects of these experimental therapies are unclear. OBJECTIVE: To systematically review the clinical results of treatments for @entity47 ( @entity47 ) and @entity47 ( @entity47 ) from the last 10 years. METHODS: MEDLINE, LILACS and SCOPUS were searched as data sources. Because the potential bias when search is limited to databases of peer-reviewed journals, reference lists were examined and experts in the field were contacted for other relevant or unpublished articles (i.e. negative studies). No negative unpublished studies were found. Studies were included related to therapeutic interventions in adult @entity47 or @entity47 @entity1 at least 3 and 12 months after non-traumatic and traumatic injuries, respectively. Eight studies met the inclusion criteria. The following interventions were reviewed: levodopa, @entity7776 , @entity2492 , @entity1772 , dorsal column stimulation and deep brain stimulation. CONCLUSIONS: The adverse effects that were associated with these treatments were typically mild. Most of the studies demonstrated considerable improvements with the interventions, but their low strength of evidence limit the generalizability of the findings.

title: Pharmacological and electrical stimulation in XXXX : new insights and future directions.

entities_list: @entity7776 :: ('MESH:D000547', 'Chemical') :: ['amantadine']

entities_list: @entity47 :: ('MESH:D018458', 'Disease') :: ['vegetative state', 'MCS', 'VS', 'minimally conscious state']

entities_list: @entity1662 :: ('MESH:D003244', 'Disease') :: ['Chronic disorders of consciousness']

entities_list: @entity1772 :: ('MESH:D001418', 'Chemical') :: ['baclofen']

entities_list: @entity2492 :: ('MESH:C049109', 'Chemical') :: ['zolpidem']

answer: @entity1662 :: (MESH:D003244,Disease) :: ['chronic disorders of consciousness']


abstract: OBJECTIVE: The purpose of this study was to determine the efficacy of the Lidopat   5% skin patch in relieving rib @entity158 . SUBJECTS AND METHODS: From June 2009 to May 2011, 44 @entity130 @entity1 with @entity174 were enrolled in this study and randomized in a double-blind method into 2 groups. The experimental group (group E: 27 @entity1 ) used a Lidopat   5% skin patch at the @entity130 site and took an oral analgesic drug for @entity158 relief. The placebo group (group P: 17 @entity1 ) used a placebo vehicle patch and an oral analgesic drug. RESULTS: The mean age, weight and hospital stay of @entity1 were 56.8    13.8 years, 67.4    12.6 kg and 6.34    1.3 days, respectively. In the first 4 days, there were no significant differences in @entity158 scores between the groups (p > 0.05). After the 5th day, the average @entity158 score was significantly less in group E (mean 1.5) than in group P (mean 3.10; p < 0.05). There was no significant difference in the number of @entity174 between groups (p = 0.904). The use of @entity6882 and the length of hospital stay (6.0 vs. 6.9 days) were both significantly less in group E (p = 0.043 and 0.009, respectively). CONCLUSION: In this study, the use of the Lidopat   5% skin patch in @entity1 with @entity174 alleviated @entity158 and shortened the hospital stay, and a lower dose of @entity158 -relieving medication was used.

title: Lidocaine Skin Patch (Lidopat   5%) Is Effective in the Treatment of XXXX : A Prospective Double-Blinded and Vehicle-Controlled Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractured ribs', 'isolated rib fractures']

entities_list: @entity6882 :: ('MESH:D008614', 'Chemical') :: ['meperidine']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['pain', 'fracture pain']

answer: @entity174 :: (MESH:D050723,Disease) :: ['Traumatic Rib Fractures']


abstract: Clinical records of one hundred pediatric @entity1 affected by @entity1723 have been analyzed. All the @entity1 have been followed since the beginning of the disease and they have had a check up on average of four months (weight, height, blood pressure, @entity4051 , @entity2690 , Triglyceridemia, renal function were evaluated). The method of home-self-monitoring was applied. After four years, and periodically thereafter, microvascular abnormalities were evaluated in all the @entity1 by @entity941 angiography. @entity16 was evaluated only in symptomatic @entity1 by peripheral nerve conduction. The average follow up period was 6.1 years (range 1-20). RESULTS: the onset of the disease was expressed in 11% of the cases by @entity772 , in 14% by @entity1270 , in the remaining cases by @entity4854 only. The severity of initial symptoms has progressively and significantly decreased in the last years. In 7% of the subjects @entity6 affected more members of the same family (4 couples of siblings and 3 couples of parent- @entity1 ). An infection preceding the onset of the disease was present in the history of 23% of the cases. Islet cell antibodies were found in 83% of the studied cases at the onset of the disease. In 80 out of the 100 @entity1 a detailed history has been obtained about the occurrence of @entity1270 episodes after the first admission and about the occurrence of severe hypoglycemic crises ( @entity410 and/or @entity772 ). 17% of the @entity1 presented at least one @entity1270 episode after the first admission (the main cause was infection before 12 years of age, an emotional problem thereafter).(ABSTRACT TRUNCATED AT 250 WORDS)

title: [ @entity2690 -dependent XXXX . Study and follow-up of 100 cases].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'child']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['Neuropathy']

entities_list: @entity1270 :: ('MESH:D007662', 'Disease') :: ['ketoacidosis']

entities_list: @entity941 :: ('MESH:D019793', 'Chemical') :: ['fluorescein']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

answer: @entity6 :: (MESH:D003920,Disease) :: ['diabetes mellitus']